NEW YORK (GenomeWeb News) – CBLPath today announced the New York State Department of Health has approved it to offer PCR-based testing of T-cells and B-cells.
Based in Rye Brook, NY, CBLPath provides sub-specialized anatomic pathology and molecular diagnostic laboratory services.
In a statement, David Bryant, CEO of the company, said that the industry is undergoing a convergence of anatomic, molecular, and digital pathology, combined with radiology. "With our added molecular capabilities, CBLPath is able to harness the full power of the convergence to provide better care to patients," he said.
CBLPath will expand its menu of molecular diagnostic tests during the next several months, the company said, without elaborating.